MetaCap

Illumina Inc. (ILMN)

NASDAQ: ILMNHealth CareMedical SpecialitiesUSD

192.82-7.83 (-3.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ILMN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$29.15B
52-week range
112.65 – 309.35
Day range
191.28 – 199.24
Volume / Avg
1.95M / 2.82M
Beta
—

52-week range

$112.65$309.35

ILMN stock today

On Nov 20, ILMN ended the session at $192.82, shedding $7.83 (3.90%), versus the S&P 500's 3.70% decline. At this level, ILMN sits in the middle of its 52-week range of $112.65 to $309.35: 37.7% below the high, set on Oct 6, 2026 and 71.2% above the low. ILMN is up 47.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 55.7%.

At 33.2x trailing earnings, Illumina trades above the peer-group median of 25.7x. Its forward P/E of 31.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Illumina

Company profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Industry
Medical Specialities
CEO
Mr. Jacob Thaysen Ph.D.
Headquarters
San Diego, CA
Employees
8,600
IPO year
2000

Financial highlights

Full financials

In fiscal 2025, Illumina generated $4.34 billion in revenue, down 0.7% from fiscal 2024, its first annual decline since 2024. Net income was $850.0 million, for a net margin of 19.6% versus a median of -25.8% in the prior 5 years. Gross margin was 66.1% (up from 65.4%) and operating margin 18.6%.

Illumina annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$4.34B$4.37B$4.50B$4.58B$4.53B
Growth-0.66%-2.93%-1.75%+1.28%+39.73%
Net income$850.00M$-1.22B$-1.16B$-4.40B$762.00M
EPS (diluted)$5.45$-7.69$-7.34$-28.00$5.04

Analyst forecast

Forecast

Consensus (21 analysts)

buy

Avg. price target

$261.45+35.59%

  • Strong buy 4
  • Buy 6
  • Hold 7
  • Sell 1
  • Strong sell 3

Target range

Low $165.00High $365.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$1.34 vs $1.36
Surprise
-1.47%

ILMN news

All ILMN news

Illumina peers

Health Care sector
ILMN peer companies
CompanyPrice% ChgMarket capCompare
LHLabcorp Holdings Inc.367.13-0.47%$29.81Bvs ILMN
DGXQuest Diagnostics Incorporated258.28-0.31%$28.42Bvs ILMN
CNCCentene Corporation63.78-2.74%$31.58Bvs ILMN
GHGuardant Health Inc.145.83+0.16%$19.73Bvs ILMN
NTRANatera Inc.273.40-5.70%$39.64Bvs ILMN
HUMHumana Inc.390.00+2.63%$46.84Bvs ILMN
MOHMolina Healthcare Inc198.39-2.43%$10.36Bvs ILMN
HSICHenry Schein Inc.83.52-1.51%$9.23Bvs ILMN

Indexes, lists and sector

Illumina stock FAQ

What is Illumina's stock price today?

ILMN last traded at $192.82 as of Nov 20, 4:00 PM EST, down 3.90% on the day. Prices are delayed at least 15 minutes.

Does Illumina pay a dividend?

No. Illumina does not currently pay a regular cash dividend.

What is ILMN's P/E ratio?

ILMN trades at a trailing P/E ratio of 33.19 and a forward P/E of 31.19, compared with a median of 25.7 for its closest peers.

Is Illumina in the S&P 500?

Yes. Illumina (ILMN) is a constituent of the S&P 500 index.

Who is Illumina's CEO?

Mr. Jacob Thaysen Ph.D. is the chief executive officer of Illumina Inc., which has about 8,600 employees.

Has ILMN ever split its stock?

Yes. The most recent ILMN stock split was a 1028-for-1000 split on Jun 25, 2024, one of 2 splits on record.

What is the ILMN 52-week high?

The 52-week high for ILMN is $309.35 and the 52-week low is $112.65. The stock is currently 37.7% below its high.

Compare ILMN